94 pages •
By Infiniti Research Limited
• Aug 2016
pain relief drug October 2015: Alder BioPharmaceuticals commenced its pivotal clinical trials for ALD## (a transformative monoclonal antibody targeting CGRP) being developed for the prevention of frequent episodic migraine October 2015: CoLucid Pharmaceuticals initiated Phase III long-term
IN JULY 2014, GSK RECALLED PANADOL ADVANCE ## CT PAIN RELIEF PRODUCTS FROM PUERTO RICO CONSUMERS, AS IT LACKED A CHILD RESISTANT FEATURE AND IS NOT LABELED AS A PRODUCT " FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN".